• 1
    Fehm T, Sagalowsky A, Clifford E, Beitsch P, Saboorian H, Euhus D, Meng S, Morrison L, Trucker T, Lane N, Ghadimi BM, Heselmeyer-Haddad K, et al. Cytogenetic evidence that circulating epithelial cells in patients with carcinoma are malignant. Clin Cancer Res 2002; 8: 207384.
  • 2
    Pretlow T, Schwartz S, Giaconia JM, Wright AL, Grimm HA, Edgehouse NL, Murphy JR, Markowitz SD, Jamison JM, Summers JL, Hamlin CR, MacLenan GT, et al. Prostate cancer and other xenografts from cells in peripheral blood of patients. Cancer Res 2000; 60: 40336.
  • 3
    Pelkey TJ, Frierson HF, Bruns DE. Molecular and immunological detection of circulating tumor cells and micrometastases from solid tumors. Clin Chem 1996; 42: 136981.
  • 4
    Goeminne JC, Guillaume T, Symann M. Pitfalls in the detection of disseminated non-hematological tumor cells. Ann Oncol 2000; 11: 78592.
  • 5
    Kasimir-Bauer S, Oberhoff C, Sliwinska K, Neumann R, Schindler AE, Seeber S. Evaluation of different methods for the detection of minimal residual disease in blood and bone marrow of patients with primary breast cancer: importance for clinical use? Breast Cancer Res Treat 2001; 69: 12332.
  • 6
    Engel H, Kleespies C, Friedrich J, Breidenbach M, Kallenborn A, Schöndorf T, Kolhagen H, Mallmann P. Detection of circulating tumor cells in patients with breast or ovarian cancer by molecular cytogenetics. Br J Cancer 1999; 81: 116573.
  • 7
    Martin VM, Siewert C, Scharl A, Harms T, Heinze R, Öhl S, Radbruch A, Miltenyi S, Schmitz J. Immunomagnetic enrichment of disseminated epithelial tumor cells from peripheral blood by MACS. Exp Hematol 1998; 26: 25264.
  • 8
    Beitsch PD, Clifford E. Detection of circulating cells in the blood of breast cancer patients. Am J Surg 2000; 180: 4469.
  • 9
    Pantel K, Otte M. Occult micrometastasis: enrichment, identification and characterization of single disseminated tumor cells. Semin Cancer Biol 2001; 11: 32737.
  • 10
    Diel IJ, Cote RJ. Bone marrow and lymph node assessment for minimal residual disease in patients with breast cancer. Cancer Treat Rev 2000; 26: 5365.
  • 11
    Partridge M, Phillips E, Francis R, Li SR. Immunomagnetic separation for enrichment and sensitive detection of disseminated tumor cells in patients with head and neck SCC. J Pathol 1999; 189: 36877.
  • 12
    Witzig TE, Bossy B, Kimlinger T, Roche PC, Ingle JN, Grant C, Donohue J, Suman VJ, Harrington D, Torre-Bueno J, Bauer KD. Detection of circulating cytokeratin-positive cells in the blood of breast cancer patients using immunomagnetic enrichment and digital microscopy. Clin Cancer Res 2002; 8: 108591.
  • 13
    Kasimir-Bauer S, Oberhoff C, Schindler AE, Seeber S. A summary of two clinical studies on tumor cell dissemination in primary and metastatic breast cancer: methods, prognostic significance and implication for alternative treatment protocol. Int J Oncol 2002; 20: 102734.
  • 14
    Racila E, Euhus D, Weiss AJ, Rao C, McConnell J, Terstappen LW, Uhr JW. Detection and characterization of carcinoma cells in the blood. Proc Natl Acad Sci USA 1998; 95: 458994.
  • 15
    Molnar B, Ladnyi A, Tanko L, Sréter L, Tulassay Z. circulating tumor cell clusters in the peripheral blood of colorectal cancer patients. Clin Cancer Res 2001; 7: 40805.
  • 16
    Salakoglu O, Maierhofer C, Lahr G, Breit E, Scheunemann P, Heumos I, Pichlmeier U, Schlimok G, Oberneder R, Köllermann MW, Köllerman J, Speicher MR, et al. Heterogeneous proliferative potential of occult metastatic cells in bone marrow of patients with solid epithelial tumors. PNAS 2002; 99: 224651.
  • 17
    Braun S, Pantel K, Müller P, Janni W, Hepp F, Kentenich CR, Gastroph S, Wischnik A, Dimpfl T, Kindermann G, Riethmüller G, Schlimok G. Cytokeratin-positive cells in the bone marrow and survival of patients with Stage I, II, or III breast cancer. N Engl J Med 2000; 342: 52533.
  • 18
    Lippert C, Seeger H, Mueck AO. The effect of endogenous estradiol metabolites on the proliferation of human breast cancer cells. Life Science 2003; 72: 87783.
  • 19
    Song RXD, Santen RJ. Apoptotic action of estrogen. Apoptosis 2003; 8: 5560.
  • 20
    Kenny FS, Hui R, Musgrove EA, Gee JM, Blamey RW, Nicholson RI, Sutherland RL, Robertson JF. Overexpression of Cyclin D1 messenger RNA predicts for poor prognosis in estrogen receptor positive breast cancer. Clin Cancer Res 1999; 5: 206976.
  • 21
    Utsumi T, Yoshimura N, Maruta M, Takeuchi S, Ando J, Mizoguchi Y, Harada N. Correlation of cyclin D1 mRNA levels with clinico-pathological parameters and clinical outcome in human breast carcinomas. Int J Cancer 2000; 89: 3943.
  • 22
    Costa SD, Lange S, Klinga K, Merkle E, Kaufmann M. Factors influencing the prognostic role of oestrogen and progesterone receptor levels in breast cancer-results of the analysis of 670 patients with 11 years of follow-up. Eur J Cancer 2002; 38: 132934.
  • 23
    Watts CK, Brady A, Sarcevic B, de Fazio A, Musgrove EA, Sutherland RL. Antiestrogen inhibition of cell cycle progression in breast cancer cells is associated with inhibition of cyclin-dependent kinase activity and decreased retinoblastoma protein phosphorylation. Mol Endocrinol 1995; 9: 180413.